Last reviewed · How we verify
NCT04585139: ANSHIN
Assessing Non-adjunctive CGM Safety at Home and in New Markets
NA trial testing Phase 1- Introduction to Dexcom G6 CGM in Diabetes Mellitus in 85 participants. Completed in 7 February 2022.
7 February 2022
Quick facts
| Lead sponsor | DexCom, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 85 |
| Start date | 6 October 2020 |
| Primary completion | 7 February 2022 |
| Estimated completion | 7 February 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Phase 1- Introduction to Dexcom G6 CGM
Conditions studied
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
DexCom, Inc.
Who can join
2 and older, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to examine whether non-adjunctive (without having to double check using another method) use of Continuous Glucose Monitoring improves A1c in adults or children with diabetes managed by intensive insulin therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessing non-adjunctive CGM safety at home and in new markets (ANSHIN).
Chao C, Andrade SB, Bergford S, Calhoun P, et al · · 2023 · cited 4× · PMID 36864014 · DOI 10.1002/edm2.414
Verify or expand the search:
- PubMed search for NCT04585139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
- NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
- NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting
Other DexCom, Inc. trials
Trials by the same sponsor.
- NCT06483945 — Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry) · recruiting
- NCT05746286 — Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia · NA · completed
- NCT04905628 — Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus · unknown
- NCT04794478 — Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System · NA · completed
- NCT04840446 — Evaluation of Modified Adhesives With Dexcom G6 Sensor · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04585139 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DexCom, Inc.
- Last refreshed: 1 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04585139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing